Citations

Clear

6728 citation(s) found for "Li, Mark".

Smartphone Passive Digital Phenotyping in Frontotemporal Lobar Degeneration
Paolillo, Emily W. , Dhanam, Sreya , Taylor, Jack C. , Sanderson-Cimino, Mark, Fregly, Ray, Saloner, Rowan, Casaletto, Kaitlin B, Kramer, Joel H, Miller, Bruce L, Seeley, William W, Gorno-Tempini, Maria Luisa, Ljubenkov, Peter A. , Rojas, Julio C, Lee, Suzee, Sturm, Virginia, Appleby, Brian, Bayram, Ece, Clark, David, Considine, Ciaran , Darby, R. Ryan , Day, Gregory S, Vito, Alyssa , Eldaief, Mark, Fields, Julie A. , Ghoshal, Nupur , Huey, Edward D, Irwin, David J, Kantarci, Kejal, Kwan, Justin , Mackenzie, Ian R. , Masdeu, Joseph C, Onyike, Chiadi U, Pantelyat, Alexander, Pascual, Belén , Popli, Tanav, Rascovsky, Katya, Rezaii, Neguine , Scholz, Sonja W. , Snyder, Allison , Tartaglia, Maria Carmela , Traynor, Bryan J, Wong, Bonnie, Kornak, John , Kremers, Walter K. , Forsberg, Leah K. , Heuer, Hilary W. , Boeve, Bradley F. , Rosen, Howard J, Boxer, Adam L, Staffaroni, Adam M. , Sanderson‐Cimino, Mark , Saloner, Rowan , Casaletto, Kaitlin B. , Kramer, Joel H. , Miller, Bruce L. , Seeley, William W. , Gorno‐Tempini, Maria Luisa , Rojas, Julio C. , Sturm, Virginia E. , Appleby, Brian S. , Day, Gregory S, Vito, Alyssa De, Eldaief, Mark C. , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Masdeu, Joseph, Onyike, Chiadi U. , Popli, Tanav A. , Tartaglia, Maria Carmela , Traynor, Bryan J. , Rosen, Howard J. , Boxer, Adam L.

Mayo Clinic

No container title available | September 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.18.26363439 | PMID 42818136 Get It

Introduction: Frontotemporal lobar degeneration (FTLD) is a devastating disease that commonly results in early onset dementia, yet its rarity and heterogeneity limit large-scale research and clinical trials. Remote monitoring via low-burden digital health tools may overcome these barriers. We evaluated clinical utility of passive smartphone monitoring in FTLD using a multi-domain mobile assessment platform. Methods: Participants were 567 adults (53% clinically normal, 21% prodromal FTLD, 26% symptomatic FTLD) who completed an in-person study visit and downloaded the ALLFTD Mobile App on their personal smartphones. The app delivered unsupervised cognitive tests and passively collected continuous data on battery percentage (proxy for smartphone use) and step count. Longitudinal follow-up included smartphone monitoring and annual in-person study visits. Primary analyses examined associations between passive smartphone features and markers of disease severity at baseline and longitudinally, and tested whether passive features added incremental value beyond app-based cognitive testing. Results: Passive smartphone features were feasible to collect and showed excellent reliability with <2 weeks of monitoring (ICCs>0.9). Features capturing smartphone use and movement demonstrated sensitivity to gold-standard clinical measures of disease severity both at baseline and longitudinally. A classification model combining passive features, the app-based cognitive composite score, and demographics detected longitudinal functional decline (AUC=0.89); passive features alone (AUC=0.84) performed comparably to a cognitive screener (AUC=0.85). Discussion: Passive smartphone monitoring is a valid, zero-burden measure of disease severity and progression in FTLD that adds modest incremental value beyond app-based cognitive testing. Findings support its use as a scalable digital endpoint in longitudinal FTLD research.
Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Cancer
Henstridge, Aylin Z. , Azorsa, Peter, Arya, Nandini , Elhossiny, Ahmed M. , Kadiyala, Padma , Goldwasser, Molly , Branch, Georgina , Sahai, Vaibhav , Peterson, Nicole , Machicado, Jorge D. , Kwon, Richard S. , Schulman, Allison R. , Wamsteker, Erik‐Jan , Philips, George, Menees, Stacy B. , Xia, Jonathan Y. , Hogenson, Tara L. , Rao, Arvind , Shi, Jiaqi , Frankel, Timothy L. , Bednar, Filip , Magliano, Marina Pasca di , Lyssiotis, Costas A. , Truty, Mark J. , Fernández-Zapico, Martín E. , Carpenter, Eileen S. , Azorsa, Peter A , Philips, George M , Pasca di Magliano, Marina , Lyssiotis, Costas A , Sahai, Vaibhav

Mayo Clinic

Cancer Research | September 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/0008-5472.can-26-0823 | PMID 42765602 Get It

Abstract Pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer, is a deadly disease with a complex tumor microenvironment (TME). Cytotoxic combination chemotherapy treatments are the mainstay of PDAC therapy, but patients rapidly develop chemoresistance, highlighting the need to elucidate how chemotherapy alters the TME and whether these changes drive chemoresistance. Here, we examined matched pre- and post-treatment tissue specimens using single-cell RNA-sequencing and found near-universal enrichment after treatment of axonal guidance genes in cancer-associated fibroblasts (CAFs). These neural CAFs were enriched near sites of perineural invasion, coinciding with regions of increased tumor cell proliferation, and were enriched in tumor areas distant from nerves after chemotherapy. Metastatic recurrent lesions had the highest prevalence of neural CAFs versus primary tumors and untreated metastases. Neural CAFs showed elevated non-canonical WNT mediators and axonal guidance genes, which complemented matching cognate binding partners in tumor epithelial cells, suggesting a role in tumor-stroma crosstalk. Additionally, in vitro studies revealed enrichment of axonal guidance genes in patient-derived CAF lines upon exposure to chemotherapy or tumor cells. Altogether, these findings implicate fibroblast-derived axonal-guidance genes in promoting PDAC invasion and point to a promising therapeutic target for this disease.
Complications of ReActiv8 for chronic low back pain: an analysis of the FDA MAUDE database
Conic, Rosalynn R. Z., Kivanc, Tugba, Fischer, Azadeh, Pasya, Sai K., Palmer, Scott, Kubrova, Eva , Eldrige, Jason S. , Hurdle, Mark FB , Hunt, Christine L., Gupta, Sahil, Kanahan Osman, Sharima, Conic, Rosalynn R.Z. , Kivanc, Tugba Yavuz, Fischer, Azadeh, Pasya, Sai Kumar Reddy , Kanahan-Osman, Sharima , Wang, Daniel , Hunt, Christine L., Gupta, Sahil

Mayo Clinic

Pain Management | September 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-7

10.1080/17581869.2026.2736037 | PMID 42762487 Get It

Maternal Postpartum Exercise Attenuates Metabolic Impairments Induced By High-fat Diet
Petsch, Ameya J., Klaus, Katherine A. , Sevits, Kyle J., Kunz, Hawley E., Kunz, Hawley , Pataky, Mark W

Mayo Clinic

Medicine & Science in Sports & Exercise | September 18, 2026 | Volume: 58 | Issue: 10S | Pages: No page available

10.1249/01.mss.0001267012.16682.58 Get It

Acute Moderate Intensity Aerobic Exercise Increases Breast Milk Exosome Concentration In Healthy Lactating Women
Gupta, Devanshi, Klaus, Katherine A. , Sevits, Kyle J., Heppelmann, Carrie J., Kim, Yohan, Szymanski, Linda M. , Lucien, Fabrice, Pataky, Leanne, Heppelmann, Carrie J. , Kim, Yohan, Lucien, Fabrice , Pataky, Mark W

Mayo Clinic

Medicine & Science in Sports & Exercise | September 18, 2026 | Volume: 58 | Issue: 10S | Pages: No page available

10.1249/01.mss.0001263472.97615.d4 Get It

Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients
Kumar, Sudhesh , Warraich, Momna , Fatima, Mahnoor , McCullough, Kristen , Al‐Kali, Aref , Alkhateeb, Hassan B. , Begna, Kebede H. , Mangaonkar, Abhishek A. , Saliba, Antoine N. , Litzow, Mark R. , Hogan, William J. , Shah, Meera , Patnaik, Mrinal M. , Pardanani, Animesh , Badar, Talha , Foran, James M. , Palmer, Jeanne, Yi, Cecilia Arana, Tefferi, Ayalew , Gangat, Naseema , Warraich, Momna , Hogan, William J , Shah, Mithun V , Foran, James M , McCullough, Kristen B , Saliba, Antoine N , Saliba, Antoine N , Palmer, Jeanne , Yi, Cecilia Arana

Mayo Clinic

American Journal of Hematology | September 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70500 | PMID 42755126 Get It

ABSTRACT Patients with newly‐diagnosed acute myeloid leukemia (ND‐AML) derive variable survival benefit from venetoclax (Ven) plus hypomethylating agent (HMA) therapy, and the optimal Ven duration across genetic risk groups remains undefined. Among 540 ND‐AML patients receiving Ven‐HMA at Mayo Clinic, outcomes were compared across Ven 7‐ ( n = 33), 14‐ ( n = 117), 21‐ ( n = 96), and 28‐day ( n = 294) schedules during Cycle 1 and stratified by ELN 2024 and Mayo genetic risk groups. At a median follow‐up of 37.7 months, allogeneic stem cell transplant (ASCT) rates were similar across Ven duration groups (15%, 18%, 18%, and 20% for 7‐, 14‐, 21‐, and 28‐day; p = 0.86). Median transplant‐censored survival was comparable across Ven durations (13.3, 11.9, 16.8, and 13.2 months for 7, 14, 21, 28 days, respectively; p = 0.65), with outcomes driven by ELN risk (6.3, 11.5, 18.3 months for high, intermediate, low; p < 0.01) and Mayo genetic risk (6.9, 17.8 months, not reached; p < 0.01). Survival was comparable across Ven durations within ELN intermediate/low‐risk and all Mayo risk groups. Among ELN high‐risk patients, 14‐day Ven was associated with inferior transplant‐censored survival compared to 21‐ and 28‐day schedules ( p < 0.01). Notably, 30‐ and 60‐day mortality were higher with shorter Ven schedules (7‐day: 9%/18%; 14‐day: 7%/15%) versus 28‐day (2%/6%), which likely reflects treatment selection bias. In ND‐AML, no significant difference in transplant‐censored survival was observed across the 7‐, 14‐, 21‐, and 28‐day Ven schedules; prognosis was determined primarily by Mayo and ELN 2024 genetic risk rather than by Ven duration. Prospective trials are needed to establish risk‐adapted Ven dosing strategies.
Engineered mRNA nanostructures expand the design space of mRNA therapeutics through programmable protein expression and immune stimulation
Knappenberger, Mark, Henry, Skylar, Kikla, Archana , Sample, Matthew, Roy, Olivia, Stephanopoulos, Nicholas , Anderson, K. S., Gustafson, Michael, Sulc, Petr , Stephanopoulos, Nicholas , Šulc, Petr , Henry, Skylar J.W. , Poppleton, Erik , Gustafson, Michael P. , Anderson, Karen S.

Mayo Clinic

No container title available | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.14.751315 | PMID 42779767 Get It

Messenger RNA (mRNA) therapeutics have transformed vaccination and protein replacement strategies, yet efforts to improve their performance have focused largely on sequence engineering, nucleotide modification, and delivery vehicles. Here we show that mRNA function can be controlled by rational design of higher-order RNA architectures. We develop self-assembling mRNA origami (mRNA-OG), a class of unimolecular RNA nanostructures that encode protein-coding sequences within higher-order, programmable, and compact nucleic acid architectures. Using computational design and experimental validation, we demonstrate that mRNA-OG folds into well-defined nanostructures while remaining translationally competent in mammalian cells. Although folded mRNA-OG recruits ribosomes comparably to unfolded constructs, it produces lower protein output, indicating that RNA architecture can directly influence translational efficiency. The compact geometry of mRNA-OG also enhances encapsulation by cationic lipid delivery systems, suggesting a structural route to improved cargo packaging. Beyond its effects on translation, mRNA architecture modulates innate immune recognition. In primary human dendritic cells, folded and unfolded mRNA-OG elicit distinct cytokine programs and differential activation of stress-response pathways, including a modest induction of the integrated stress response that is not fully explained by canonical PKR signaling. Our results establish programmable structure as a new design parameter for mRNA therapeutics that can affect its functionality, delivery properties, and immune sensing.
Widespread Loss of Heterozygosity and Endoreduplication in Odontogenic Myxoma
Stojanov, Ivan J. , Dababneh, Melad N., Cracolici, Vincent, Qureshi, Sana, Hattery, Travis , Chen, Mark , Smith, Benjamin F. , O’Neill, Diane, Wolbert, Matthew, Schneider, Keith M., Shurtleff, Sheila, Astbury, Caroline , Geiersbach, Katherine B. , Woo, Sook-Bin, Fritchie, Karen, Weber, Grace E. , Dermawan, Josephine K., Dababneh, Melad , Cracolici, Vincent , O'Neill, Diane H., Schneider, Keith M., Shurtleff, Sheila A., Woo, Sook‐Bin , Fritchie, Karen, Dermawan, Josephine K.

Mayo Clinic

American Journal of Surgical Pathology | September 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/pas.0000000000002616 | PMID 42745350 Get It

Odontogenic myxoma (OM) is an uncommon, locally aggressive odontogenic neoplasm with characteristic histologic and clinico-radiographic features but with potential for histologic overlap with other odontogenic and non-odontogenic entities and a non-specific immunoprofile. Widespread loss of heterozygosity (LOH) has been recently described in rare cases of OM. The aim of this study was to determine whether widespread LOH represents a recurrent molecular signature that can be leveraged for clinical decision-making. Allele-specific copy number variation data from chromosomal microarray were generated from 7 OM, comprising a combined prospective and retrospective cohort. Four tumors arose in the mandible and 3 in the maxilla in patients ranging in age from 18 to 94 years (median: 44), with tumor size ranging from 2.2 to 13.0 cm. Variable amounts of fibrous stroma (odontogenic “fibromyxoma”) were present in 4/7 OM, and hypercellularity not typically appreciated in conventional OM was present in 3/7 cases. All OM (7/7) demonstrated widespread LOH, with 5 cases showing a near-haploid/low hypodiploid genomes (multiple monosomies) and 2 cases showing evidence of pseudo-hyperdiploidy due to probable endoreduplication. Both pseudo-hyperdiploid cases were ≥10 cm in size; 1 represented local recurrence. Chromosomes 1 to 3, 6, 9, 11, 13, 15, and 22 demonstrated LOH in ≥75% of cases (chromosomes 1 to 3, 6, and 9 in 100% of cases), while chromosomes 5, 12, 19, and 20 universally retained heterozygosity. Altogether, widespread LOH is a recurrent event in OM and a novel finding in odontogenic pathology, and allele-specific copy number variation analysis can serve as a diagnostic adjunct in challenging cases.
Access to Primary Care and Endocrinology Care Among Medicare Beneficiaries With Type 1 and Type 2 Diabetes, 2017–2021
Robinson-Ector, Kaitlynn S. , Day, Hannah, Begle, Connor, Miller, Katherine E. M., Wieland, Mark L. , McCoy, Rozalina G., Day, Hannah, Begle, Connor, Miller, Katherine E. M. , Bazemore, Andrew , McCoy, Rozalina G.

Mayo Clinic

Diabetes Care | September 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2337/dc26-2070 | PMID 42743063 Get It

Letter: Retrospective Review of Metals Patch Testing for Implantation of Cardiac Devices or Prosthetic Orthopedic Joints
Link, Phillip J. , Maniam, Ganesh B., Youssef, Molly J. , Davis, Mark DP., Link, Jenny L. , Maniam, Ganesh

Mayo Clinic

Dermatitis® | September 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/17103568261490392 | PMID 42741884 Get It